Managers / Q4 2019 · view latest →
Lion Point Capital, LP
CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200
Summary
Lion Point Capital, LP reported $1.1B in U.S.-listed holdings across 26 positions for Q4 2019.
Its largest position, CSIQ, represents 9.0% of the portfolio.
Compared with Q3 2019, the fund opened 3 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 51.3% · $552M
- ETP · 46.8% · $504M
- Other · 2.0% · $21M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CPE3EURCALLON PETE CO DEL | NEW | +8.20M | 8.20M | +$40M | $40M |
| SPDR S&P 500 ETF TR | NEW | +103.9K | 103.9K | +$33M | $33M |
| NLNKUSDNEWLINK GENETICS CORP | NEW | +3.11M | 3.11M | +$8M | $8M |
| ALDER BIOPHARMACEUTICALS INC | SOLD OUT | −53.52M | 0 | −$59M | $0 |
| CRZOEURCARRIZO OIL & GAS INC | SOLD OUT | −4.67M | 0 | −$40M | $0 |
| FSLRFIRST SOLAR INC | SOLD OUT | −611.9K | 0 | −$35M | $0 |
| ALDR1EURALDER BIOPHARMACEUTICALS INC | SOLD OUT | −1.20M | 0 | −$23M | $0 |
| MEDICINES CO | SOLD OUT | −5.00M | 0 | −$6M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $17M | 35 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $19M | 39 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $18M | 27 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $15M | 19 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $16M | 21 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $19M | 19 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $45M | 25 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $55M | 27 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $179M | 32 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $200M | 30 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $224M | 31 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $221M | 30 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $243M | 31 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $703M | 32 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $454M | 41 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $878M | 40 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $431M | 35 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $373M | 33 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $533M | 38 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $579M | 34 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $550M | 30 | May 19, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2020 | $519M | 24 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $456M | 24 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $412M | 24 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $379M | 25 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.1B | 26 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $897M | 26 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.0B | 24 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.1B | 24 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $636M | 35 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.